omniture

Sinovac Schedules 2011 Annual Meeting of Shareholders

2011-06-07 18:00 1804

BEIJING, June 7, 2011 / PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2011 Annual Meeting of Shareholders on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of May 25, 2011 will be eligible to vote and are invited to attend.

Sinovac 2010 annual report and the proxy statements are also available on the company's website: http://www.sinovac.com/?optionid=751

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched in 2011.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee

 

 

Sinovac Biotech Ltd.

 

 

Tel:  +86-10-8279-9871/9659

 

 

Fax:  +86-10-6296-6910

 

 

Email: ir@sinovac.com

 

 

 

 

Investors:

 

 

Stephanie Carrington/Amy Glynn

 

 

The Ruth Group

 

 

Tel:  +1-646-536-7017/7023

 

 

Email: scarrington@theruthgroup.com

 

 

aglynn@theruthgroup.com

 

 

 

 

Media

 

 

Jason Rando

 

 

The Ruth Group

 

 

Tel:  +1-646-536-7025

 

 

Email:  jrando@theruthgroup.com

 

 

 




Source: Sinovac Biotech Ltd.
Related Stocks:
NASDAQ:SVA
collection